Document Detail


Drug-Eluting Stents May Not Reduce Target Lesion Revascularization in Cardiac Allograft Vasculopathy.
MedLine Citation:
PMID:  24383617     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Although drug-eluting stent (DES) compared with bare metal stent (BMS) use reduces in-stent restenosis (ISR) in traditional coronary artery disease, its efficacy in cardiac allograft vasculopathy (CAV) has not been clearly established.
BACKGROUND: CAV is a leading cause of mortality after the first year following cardiac transplantation. CAV treatment options are limited, and DES use has increased significantly in this population.
METHODS: In a retrospective study of heart transplant patients at our institution who underwent percutaneous coronary intervention with a BMS or DES for CAV, we compared baseline characteristics, clinical outcomes, ISR, and target lesion revascularization (TLR). The primary end-point was angiographic ISR assessed by quantitative coronary angiography analyzed as both a binary (≤50% vs. >50%) and continuous variable (follow-up minimal luminal area [MLA]/baseline MLA). Secondary outcomes included TLR and a composite of death, myocardial infarction, heart failure, and retransplantation.
RESULTS: In 45 patients with DES, BMS, or both, ISR assessed as a continuous variable was statistically different between the 2 stent groups (follow-up MLA/baseline MLA = 0.796 DES vs. 0.481 BMS; P = 0.0037). There was also a significant difference in ISR (10.8% for DES versus 30.7% for BMS) when assessed as a binary variable. There was no statistically significant difference in TLR or composite cardiovascular outcomes between groups when adjusted for traditional cardiovascular risk factors.
CONCLUSIONS: ISR assessed as a continuous variable was significantly different between stent groups. However, this did not lead to a difference in TLR or cardiovascular outcomes. This hypothesis-generating finding suggests that patients with CAV may not necessarily need treatment with DES, which can be more costly and carries more potential risk than BMS.
Authors:
Ki E Park; Tianyao Huo; Keith E Muller; Juan M Aranda; James A Hill; R David Anderson
Related Documents :
24839977 - Strategies to improve cardiac resynchronization therapy.
17453137 - Percutaneous coronary interventions in europe: prevalence, numerical estimates, and pro...
23575307 - Mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation ...
25043397 - Diagnostic value of supar in differentiating non-cardiac pleural effusions from cardiac...
19543847 - Left ventricular accessory chamber: a case report and review of the literature.
24304537 - Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation i...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-1-2
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  -     ISSN:  1540-8183     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014, Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Excess body mass index loss predicts metabolic syndrome remission after gastric bypass.
Next Document:  Techniques for the Analysis of Cysteine Sulfhydryls and Oxidative Protein Folding.